Article Image: Trial Suggests Russia's COVID-19 Vaccine is 91.6% Effective

Article Image: Trial Suggests Russia's COVID-19 Vaccine is 91.6% Effective

After criticism previous year for an early rollout, Russia's Sputnik V vaccine is 91.6% effective against symptomatic Covid-19 and 100% effective against severe and moderate disease, according to an interim analysis of the vaccine's Phase 3 trial results.

"The development of the Sputnik V vaccine has been criticised for unseemly haste, corner cutting, and an absence of transparency", wrote the British scientists Ian Jones and Polly Roy.

"Another vaccine can now join the fight to reduce the incidence of COVID-19", they said.

The results were based on data from 19,866 volunteers, of whom a quarter received a placebo, the researchers, led by the Gamaleya Institute's Denis Logunov, said in The Lancet. Sixty two cases were found in the placebo group - equating to an efficacy of 91.6%.

"India is a key partner in terms of production of vaccine and we expect that there'll be a restricted emergency use order for the Sputnik V vaccine.this month or next". Serbia and Belarus have both green-lit the vaccine.

"We are in talks with China, Russia and some other countries for procurement of the [Covid-19] vaccine after narrowing down our priority list", Dr Sultan had said.

Pfizer's shot had the highest efficacy rate at 95pc, closely followed by Moderna's vaccine and Sputnik V while AstraZeneca's vaccine had an average efficacy of 70pc.

But scientists said its benefit has now been demonstrated.

Russian Federation approved the drug for emergency use in August, before phase 3 trials, and started giving it to the public in December.

Russian Federation began rolling out Sputnik V in a large-scale vaccination campaign in December, with doctors and teachers the first in line to get the shot.

Small numbers of frontline health workers began receiving it soon after and a large-scale rollout started in December, though access was limited to those in specific professions, such as teachers, medical workers, and journalists.

The success of the vaccine restores Russian research capabilities to the world's top echelons, after the sector had been decimated by crises and corruption in the wake of the USSR's collapse in 1991.

In early January, the Russian Direct Investment Fund that bankrolled the jab said that over 1 million Russians have already been vaccinated with the domestically developed shot.

Google Maps Rolls Out Split-Screen Street View for Android Users
But, if you are using Street View directly from a location's listing, the app will instead give you a regular fullscreen section. The feature launches automatically after dropping a pin and going into Street View , you don't have to do anything special.

"The Lancet did very unbiased work despite some of the political pressures that may have been out there", he said.

"This is a useful addition to the published data on Covid-19 vaccine effectiveness", Dr.

The Mexican government on Tuesday also launched a new website for people over the age of 60 to register for vaccination appointments.

The study included more than 2,100 people over 60, and the vaccine appeared to be about 92% effective in them. Out of the total 19,866 participants, 16 cases of symptomatic Covid-19 were confirmed in the vaccine group 21 days after the first vaccine dose.

And there were no deaths or serious illness in the vaccinated group linked to the jab.

"Further research is needed to understand the efficacy of the vaccine on asymptomatic Covid-19, and transmission", Tang said.

Sputnik V has so far been administered to more than 2 million people worldwide.

The vaccine has already been sent to other countries, including some in South America like Argentina and Bolivia.

Denouncing European delays, Viktor Orban's Hungary sidestepped the European Medicines Agency (EMA) and registered the vaccine on its own. Russian Federation made the vaccine available to the wider public in December, when Europe and the United States were just deploying the first doses of the vaccines made by their pharmaceutical companies.

Germany has said it would use Sputnik V if it is approved by Europe's drug regulator while France has said it could buy any efficient vaccine.

Rather than exporting Sputnik V in bulk, Moscow hopes to develop production partnerships with local factories.

"We will also be starting production in China later this month". Trial doses have also been produced by a manufacturer in Brazil.

Last spring, Alexander Gintsburg, the director of the state-run Gamaleya research centre that developed Sputnik V, boasted of having personally injected himself with an experimental version of the jab.

Related Articles